Effect of statins on LDL cholesterol and lower risk of cardiovascular complications. Which medication to choose?
https://doi.org/10.21518/2079-701X-2016-4-10-15
Abstract
Primary and secondary prevention of cardiovascular complications (CVC) has been one of the key areas in modern cardiology over the past decades. The article examined the relationship between the risk of CVC and the lipid metabolism parameters. The article discussed the major clinical trials the results of which constitute the evidence base for statins use to reduce the risk of acute coronary and cerebrovascular events.
About the Authors
N. M. Savina
Central State Medical Academy of the Presidential Administration
Russian Federation
Russian Federation
B. A. Sidorenko
Central State Medical Academy of the Presidential Administration
Russian Federation
Russian Federation
References
1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003, 326: 1423-1427.
2. Istvan E. Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atherosclerosis, 2003, 4: 3-8.
3. Schaefer EJ, McNamara JR, Tayler T et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol, 2004, 93(1): 31-9.
4. Nissen SE, Tuzcu EM, Schoenhagen P Brown BG. REVERSAL Investigators. Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004, 3(9): 1071-80.
5. Okazaki S, Yokoyama T, Miyauchi K. Early Statin Treatment in Patients With Acute Coronary Syndrome. Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation, 2004, 110: 1061-1068.
6. Nissen S, Nicholls S, Sipahi I. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTERIOD trial. JAMA, 2006, 295: 1556-1565.
7. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation, 2004, 109(23): 39-43.
8. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet, 1996, 348: 1079-82.
9. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J, 2003, 24: 225-48.
10. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ, 2000, 321: 1-5.
11. La Rosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. JAMA, 1999, 282: 2340-6.
12. Athyros V, Papageorgiou A, Mercouris B. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart desease prevention. The GREACE study. Current Medical Research Opinion, 2002, 18(4): 220-228.
13. Pedersen TR, Faergeman O, Kastelein JJ. High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. The IDEAL Study: A Randomized Controlled Trial. JAMA, 2005, 294: 2437-2445.
14. Недогода С.В. Почему аторвастатин имеет преимущества в «ограничительных» списках? РМЖ, 2010, 10: 638-641.
15. Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev, 2015, 3: CD008226.
16. Агеев Ф.Т. Аторвастатин: классические исследования и их современная интерпретация. Доказательная база аторвастатина для практического врача. Атмосфера. Новости кардиологии, 2015, 2: 26-30.
17. Schwartz GG, Olsson AG, Ezekowitz MD et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA, 2001, 285: 1711-18.
18. Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004, 350(15): 1495-1504.
19. Ray KK, Cannon CP, McCabe CH. PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol, 2005, 46(8): 1405-1410.
20. Muhlestein JB, Anderson JL, Horne BD et al. Early effects of statins in patients with coronary artery disease and high C-reactive protein. Am J Cardiol, 2004, 94: 1107-12.
21. Ridker PM, Cannon CP, Morrow D et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 2005, 352(1): 20-28.
22. Nedogoda S.V. Why atorvastatin has benefits in "restrictive" lists? RMZ, 2010, 10: 638-641.
23. Ageev F.T. Atorvastatin: classical trials and their current interpretation. The evidence base for atorvastatin for practitioner. Atmosphera. Novosti Kardiologii, 2015, 2: 26-30.
Review
For citations:
Savina NM, Sidorenko BA. Effect of statins on LDL cholesterol and lower risk of cardiovascular complications. Which medication to choose? Meditsinskiy sovet = Medical Council. 2016;(4):10-15. (In Russ.) https://doi.org/10.21518/2079-701X-2016-4-10-15
Views:
978
Email this article 